Immunoselective Cell Growth Inhibition by Antibody-Adriamycin Conjugates Targeting c-erbB-2 Product on Human Cancer Cells

Monoclonal antibodies targeting c-erbB-2 protooncogene product p185 were conjugated with adriamycin via a pH-sensitive spacer. The resultant antibody-adriamycin conjugates showed immunoselective binding, internalization and cytotoxicity to p185-positive human breast cancer cell SKBr-3 and gastric ca...

Full description

Saved in:
Bibliographic Details
Published inBiological & pharmaceutical bulletin Vol. 18; no. 9; pp. 1279 - 1282
Main Authors SUZUKI, Shinya, TANAKA, Megumi, MASUKO, Takashi, HASHIMOTO, Yoshiyuki
Format Journal Article
LanguageEnglish
Published Tokyo The Pharmaceutical Society of Japan 1995
Maruzen
Japan Science and Technology Agency
Subjects
adriamycin
Antibiotics, Antineoplastic - pharmacology
Antineoplastic agents
Biological and medical sciences
Cell Division - drug effects
Chemotherapy
Doxorubicin - pharmacology
Humans
Immunotoxins - pharmacokinetics
Immunotoxins - pharmacology
internalization
Medical sciences
monoclonal antibody
Neoplasms - pathology
Neoplasms - therapy
Pharmacology. Drug treatments
Receptor, ErbB-2 - analysis
Receptor, ErbB-2 - immunology
Tumor Cells, Cultured
Antineoplastic agent
Human
Cytotoxicity
Monoclonal antibody
Immunoconjugate
In vitro
Target
Cell line
C-Onc gene
Internalization
Anthracyclins
Chemical uptake
Tumor cell
Protooncogene
Online AccessGet full text

Cover

More Information
Summary:Monoclonal antibodies targeting c-erbB-2 protooncogene product p185 were conjugated with adriamycin via a pH-sensitive spacer. The resultant antibody-adriamycin conjugates showed immunoselective binding, internalization and cytotoxicity to p185-positive human breast cancer cell SKBr-3 and gastric cancer cell MKN-7, but not to normal human lymphocytes.
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-1
content type line 23
ISSN:0918-6158
1347-5215
DOI:10.1248/bpb.18.1279